91 related articles for article (PubMed ID: 15934518)
1. Clinical trials referral resource. Current clinical trials of BAY 43-9006, Part 1.
Wright JJ; Zerivitz K; Gravell A
Oncology (Williston Park); 2005 Apr; 19(4):499-502. PubMed ID: 15934518
[No Abstract] [Full Text] [Related]
2. Clinical trials referral resource. Current clinical trials of thalidomide.
Streicher HZ; Vereshchagina LA; Schoenfeldt M
Oncology (Williston Park); 2003 Mar; 17(3):369-71, 374-5, 379-80. PubMed ID: 12661268
[No Abstract] [Full Text] [Related]
3. Clinical trials referral resource.
Wright JJ; Zerivitz K; Gravell A
Oncology (Williston Park); 2005 May; 19(6):722, 725-6, 728 passim. PubMed ID: 15971449
[No Abstract] [Full Text] [Related]
4. Spiny follicular hyperkeratosis eruption: a new cutaneous adverse effect of sorafenib.
Franck N; Barete S; Moguelet P; Blanchet B; Carlotti A; Ropert S; Avril MF; Francès C; Billemont B; Goldwasser F
J Clin Oncol; 2010 Nov; 28(31):e640-2. PubMed ID: 20855839
[No Abstract] [Full Text] [Related]
5. Clinical trials referral resource. Current clinical trials investigating 3-AP.
Low JA; Schoenfeldt M
Oncology (Williston Park); 2005 Mar; 19(3):354, 357-8. PubMed ID: 15828551
[No Abstract] [Full Text] [Related]
6. [Clinical studies with sorafenib (Nexavar) in metastatic melanoma].
Hauschild A
J Dtsch Dermatol Ges; 2007 Apr; 5(4):345. PubMed ID: 17376105
[No Abstract] [Full Text] [Related]
7. A new way to attack cancer.
Stipp D
Fortune; 2000 May; 141(11):164-6, 168, 172 passim. PubMed ID: 10947559
[No Abstract] [Full Text] [Related]
8. Can a rational design for metronomic chemotherapy dosing be devised?
Maraveyas A; Lam T; Hetherington JW; Greenman J
Br J Cancer; 2005 Apr; 92(8):1588-90. PubMed ID: 15846302
[No Abstract] [Full Text] [Related]
9. Examining heterogeneity in phase II trial designs may improve success in phase III.
Tuma RS
J Natl Cancer Inst; 2008 Feb; 100(3):164-6. PubMed ID: 18230788
[No Abstract] [Full Text] [Related]
10. Clinical trials of note. Sorafenib as adjuvant treatment in the prevention of disease recurrence in patients with hepatocellular carcinoma (HCC) (STORM).
Printz C
Cancer; 2009 Oct; 115(20):4646. PubMed ID: 19806596
[No Abstract] [Full Text] [Related]
11. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006.
Govindarajan R; Adusumilli J; Baxter DL; El-Khoueiry A; Harik SI
J Clin Oncol; 2006 Oct; 24(28):e48. PubMed ID: 17008686
[No Abstract] [Full Text] [Related]
12. Angiogenesis as a therapeutic target.
Ferrara N; Kerbel RS
Nature; 2005 Dec; 438(7070):967-74. PubMed ID: 16355214
[TBL] [Abstract][Full Text] [Related]
13. Clinical trials referral resource. Current clinical trials administering the antiangiogenesis agent SU5416.
Via LE; Gore-Langton RE; Pluda JM
Oncology (Williston Park); 2000 Sep; 14(9):1312, 1315-6, 1321-3. PubMed ID: 11033829
[No Abstract] [Full Text] [Related]
14. Metronomic chemotherapy: teaching old drugs new tricks?
Vogelzang N
Clin Adv Hematol Oncol; 2004 Jul; 2(7):432-3. PubMed ID: 16163217
[No Abstract] [Full Text] [Related]
15. Angiogenesis inhibitors: from laboratory to clinical application.
Nakamura T; Matsumoto K
Biochem Biophys Res Commun; 2005 Jul; 333(2):289-91. PubMed ID: 15953588
[No Abstract] [Full Text] [Related]
16. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: Is rash associated with treatment outcome?
Strumberg D; Awada A; Hirte H; Clark JW; Seeber S; Piccart P; Hofstra E; Voliotis D; Christensen O; Brueckner A; Schwartz B
Eur J Cancer; 2006 Mar; 42(4):548-56. PubMed ID: 16426838
[TBL] [Abstract][Full Text] [Related]
17. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results.
Egberts F; Kahler KC; Livingstone E; Hauschild A
Onkologie; 2008 Jul; 31(7):398-403. PubMed ID: 18596389
[TBL] [Abstract][Full Text] [Related]
18. Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.
Strumberg D; Clark JW; Awada A; Moore MJ; Richly H; Hendlisz A; Hirte HW; Eder JP; Lenz HJ; Schwartz B
Oncologist; 2007 Apr; 12(4):426-37. PubMed ID: 17470685
[TBL] [Abstract][Full Text] [Related]
19. [Metronomic chemotherapy in pediatric oncology: hype or hope?].
André N; Pasquier E; Verschuur A; Sterba J; Gentet JC; Rössler J
Arch Pediatr; 2009 Aug; 16(8):1158-65. PubMed ID: 19446445
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib: delivering a targeted drug to the right targets.
Flaherty KT
Expert Rev Anticancer Ther; 2007 May; 7(5):617-26. PubMed ID: 17492926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
